Back to top
more

Lineage Cell Therapeutics (LCTX)

(Delayed Data from AMEX)

$1.15 USD

1.15
690,766

-0.10 (-8.00%)

Updated Apr 16, 2024 03:52 PM ET

After-Market: $1.15 0.00 (0.00%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LCTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Lineage Cell Therapeutics, Inc. [LCTX]

Reports for Purchase

Showing records 1 - 20 ( 97 total )

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/12/2024

Company Report

Pages: 4

BUY: Spends $25M in 2023, and $35M in Cash Plus $14M - Funded through 3Q2025

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/08/2024

Company Report

Pages: 9

2023 Results; Updated OpRegen Durability Impresses Solidifying Roche''s Global Partner Role

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/22/2024

Company Report

Pages: 4

BUY: FDA Clears IND (amendment) for OPC1 Cell Transplant for Spinal Cord Injury

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/13/2024

Daily Note

Pages: 7

Regulatory Green Light For OPC1 and DOSED Study Represents Important Day For LCTX

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/18/2023

Daily Note

Pages: 7

OPC1''s IND Amendment Submitted For SCI; Awaiting FDA Decision to Kickstart DOSED Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/20/2023

Company Report

Pages: 4

BUY: Reports the Quarter - Stock Makes New Lows, Lowering Price Target from $6 to $2

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/10/2023

Company Report

Pages: 8

3Q23 Results; OpRegen Focused on Differentiation; Pipeline Progressing as Planned

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/05/2023

Company Report

Pages: 7

Global Partner Genentech Reveals Rapid and Sustained Benefits of OpRegen in GA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/22/2023

Company Report

Pages: 4

BUY: OPREGEN P1/2A Additional Results to be Featured at the 23rd EURETINA Congress

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/06/2023

Daily Note

Pages: 5

Cell Therapy Pipeline Expands as Development Activities Commence For Partnered Neurology Candidates

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/11/2023

Company Report

Pages: 14

2Q23 Results; Pipeline Buzzing and OpRegen Global Partner Pushes Forward; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/25/2023

Company Report

Pages: 4

BUY: Lineage Cell Cancer Research UK: Topline Phase 1 Data of VAC2 in Advanced NSCLC- Early Data Appears Promising

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

07/24/2023

Daily Note

Pages: 7

VAC2 Phase 1 Data Highlight the Potential of Using a Cancer Vaccine in NSCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

07/05/2023

Company Report

Pages: 9

We See Important Convergence of Strategy Coming for Spinal Cord Injury; Thoughts Post-First Annual SCI Investor Conf

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/12/2023

Company Report

Pages: 11

1Q23 Results; Perfect Timing to Push for OPC1 and VAC2 While OpRegen Phase 1/2a Progresses as Planned

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

04/26/2023

Company Report

Pages: 5

BUY: OpRegen P1/2a - Proof of Concept Presented

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/26/2023

Company Report

Pages: 11

Global Partner Genentech Makes OpRegen Statement at ARVO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/13/2023

Company Report

Pages: 5

BUY: Lineage Cell Therapeutics Highlights Clinical Progress, Closes the Year with $58M in Cash.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/10/2023

Company Report

Pages: 10

2022 Results; OPC1 Makes Progress With Regulatory Discussions in Spinal Cord Injury Planned

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party